The five-star InterContinental lies in the heart of Porto’s historic centre and is the gem in the city's accommodation crown. As a converted monastery-cum-palace, the hotel exudes character, and when paired with the staff’s diligent hospitality, it offers an outstanding all-round experience.
Hotel Infante Sagres, member of the “Small Luxury Hotels of the World” is a truly unique hotel located in the heart of Porto’s historical district, two steps away from the city’s UNESCO World Heritage area.
Biosimilars & Biologics will address issues around biosimilars science, global regulatory pathways, evidence for clinical applications, and education for prescribers and patients that are key to successful uptake of these products.
In this Summit you will learn more about doing partnership and commercialize CDx tests with pharmaceutical and biotech companies. We will also provide solutions to assist in all stages of CDx development from the biomarker discovery process through CDx commercialization.
This year’s flagship event will gather top EU, US, Asia and global regulators, officials, healthcare actors as well as industry leaders, to foster open exchange and debate on the role of the biosimilar & biologics medicines sector.
The 2nd Annual Companion Diagnostics & Biomarkers 2019 will provide valued information about new IVD regulations, Dx reimbursement strategy, market access strategy to ensure successful commercialization with pharma & biotech companies.
Biobanking 2018 is the leading event to get through the biobanking’s ever-thriving market and convenes key stakeholders from the field, and innovator pharmaceutical manufacturers, payers, providers and patient advocates addressing timely challenges and best practices for biobanking product success.
Biosimilars & Biologics 2019 is the leading event to continually stay on the pulse of the biosimilars’ ever-changing market and convenes key stakeholders including biosimilar and innovator pharmaceutical manufacturers, payers, providers and patient advocates addressing timely challenges and best practices for biosimilar product success